In addition, analysis has shown that the level of ARID1B expression is associated with the disease-free survival of breast cancer patients, and that the 5-year survival rate of ARID1B-positive patients is significantly lower than that of ARID1B-negative patients [19]. Here, ARID1B is linked to breast carcinoma.